Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Leukemic Transformation - From the 2024 Seattle Patient and Family Conference
Topic(s)
Related Bone Marrow Failure Diseases and Malignancies
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Anna Halpern, MD
Dr. Anna Halpern explains how bone marrow failure diseases can advance into certain leukemias in this session from the 2024 Seattle Patient and Family Conference.
Inherited Bone Marrow Failure - From the 2024 Seattle Patient and Family Conference
Topic(s)
Related Bone Marrow Failure Diseases and Malignancies
Pediatric Bone Marrow Failure Diseases
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Presenter(s)
Sioban Keel, MD
Which bone marrow failure conditions can be inherited? What is the likelihood of inheriting aplastic anemia, PNH, or MDS? Find out in this session that features Dr. Sioban Keel.
What is my Diagnosis? From the 2024 Seattle Patient and Family Conference
Topic(s)
Related Bone Marrow Failure Diseases and Malignancies
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Bart Scott, MD
Dr. Bart Scott explains the diagnosis bone marrow failure diseases in this session from the 2024 Patient and Family Conference in Seattle, WA.